Kiniksa Pharmaceuticals, Ltd. (KNSA) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-K	10-K	10-K	10-K	S-1
Revenues	220.2	38.5	0.0	0.0	0.0	0.0	0.0
Revenue growth	471.2%
Cost of goods sold	47.0	9.9	0.0	0.0	0.0	0.0	0.0
Gross profit	173.2	28.6	0.0	0.0	0.0	0.0	0.0
Gross margin	78.7%	74.2%
Selling, general and administrative [+]	98.0	85.9	45.3	35.0	21.6	9.0	6.6
General and administrative					21.6	9.0	6.6
Research and development	65.5	99.3	112.0	135.0	86.6	56.4	17.4
EBITDA [+]	12.2	-154.3	-155.0	-167.9	-107.9	-65.4	-24.0
EBITDA growth	-107.9%	-0.4%	-7.7%	55.6%	65.0%	172.6%
EBITDA margin	5.5%	-400.3%
Depreciation and amortization	2.4	2.4	2.4	2.1	0.3	0.0	0.0
EBIT [+]	9.8	-156.6	-157.4	-170.0	-108.2	-65.4	-24.0
EBIT growth	-106.2%	-0.5%	-7.4%	57.1%	65.4%	172.5%
EBIT margin	4.4%	-406.4%
Interest income				6.0	4.7	0.5	0.1
Interest income				6.0	4.7	0.5	0.1
Other income (expense), net [+]	1.3	0.1	1.1
Other non-operating income	1.3	0.1	1.1
Pre-tax income	11.0	-156.5	-156.2	-163.9	-103.4	-64.9	-23.9
Income taxes	-172.3	1.4	5.2	-2.0	-0.2	0.0	0.0
Tax rate				1.2%	0.2%
Net income	183.4	-157.9	-161.4	-161.9	-103.2	-64.9	-24.0
Net margin	83.3%	-409.7%

Basic EPS [+]	$2.64	($2.30)	($2.61)	($2.99)	($3.49)	($35.85)	($91.61)
Growth	-214.8%	-11.8%	-12.9%	-14.3%	-90.3%	-60.9%
Diluted EPS [+]	$2.60	($2.30)	($2.61)	($2.99)	($3.49)	($35.85)	($91.61)
Growth	-213.1%	-11.8%	-12.9%	-14.3%	-90.3%	-60.9%

Shares outstanding (basic) [+]	69.4	68.6	61.8	54.0	29.5	1.8	0.3
Growth	1.2%	10.9%	14.4%	82.9%	1532.7%	591.5%
Shares outstanding (diluted) [+]	70.4	68.6	61.8	54.0	29.5	1.8	0.3
Growth	2.7%	10.9%	14.4%	82.9%	1532.7%	591.5%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.